Bio-Techne Launches Innovative Neurological Assays
Bio-Techne Corporation (NASDAQ: TECH) has unveiled its latest innovation, the Simple Plex Ultra-Sensitive Assays, specifically designed for the Ella automated benchtop platform. This advancement marks a significant leap forward in the detection and analysis of low-abundance proteins in blood, particularly useful for researchers studying neurodegenerative diseases.
Revolutionizing Disease Detection
The new assays offered by Bio-Techne enable the detection of proteins at femtogram concentrations, providing researchers with critical insights much earlier in the disease process than previously possible. Traditional methods have struggled to identify such low levels of biomarkers in blood, which often hampers early diagnosis and treatment strategies for conditions like Alzheimer's, ALS, multiple sclerosis, Parkinson's disease, and traumatic brain injury.
Enhanced Accuracy for Neurodegenerative Disease Research
These ultra-sensitive assays are a game-changer for scientific research, offering enhanced analytical capabilities. They allow for the reliable quantification of biomarkers crucial for understanding neurodegenerative diseases, including neurofilament light chain (NFL), glial fibrillary acidic protein (GFAP), phosphorylated tau (pTau 217), and amyloid-beta (aa1-42). By detecting these proteins at such low concentrations, researchers can observe subtle biological changes and monitor disease progression more effectively.
Impact on Research and Development
As additional research unfolds, the Simple Plex Ultra-Sensitive Assays position Bio-Techne as a leader in the field of immunoassays. These assays build on the proven performance of the Ella system, which has been cited in over 200 peer-reviewed publications focused on neurology. Their automated workflow ensures minimized manual handling, reducing variability and increasing reliability in data collection.
Streamlined Process and Efficiency
The runtime for obtaining results with these assays is under three hours, showcasing a significant reduction in time otherwise spent on manual testing methods. The automated features of the Ella platform drive high-throughput studies, which are essential for defining disease trajectories and uncovering new therapeutic targets.
Supporting Neurodegenerative Research and Treatment
This launch not only strengthens Bio-Techne's position in the immunoassay market but also serves to advance precision medicine by elevating the standard of biomarker detection in neuroscience research. The studies enabled by these assays are vital for developing new treatment strategies, ultimately benefiting patients who suffer from these debilitating diseases.
About Bio-Techne Corporation
Bio-Techne Corporation (NASDAQ: TECH) is a global leader in life sciences, supplying innovative tools and bioactive reagents to the research and clinical diagnostic communities. With a product portfolio that includes hundreds of thousands of items, the company reported over $1.2 billion in net sales in recent fiscal years and employs around 3,100 professionals worldwide. Bio-Techne continues to push boundaries in scientific research, enhancing our understanding of complex biological systems and improving clinical outcomes.
Frequently Asked Questions
What are Simple Plex Ultra-Sensitive Assays?
They are advanced assays developed by Bio-Techne that allow for the detection of low-abundance proteins in blood, specifically designed for neurological research.
How do these assays improve disease detection?
These assays enable femtogram-level detection of biomarkers, providing researchers with the ability to identify early biological changes associated with neurodegenerative diseases.
What is the runtime for these assays?
The total runtime for obtaining assay results is under three hours, making it a fast and efficient process for researchers.
Which diseases can benefit from these assays?
Conditions such as Alzheimer’s, ALS, multiple sclerosis, Parkinson’s disease, and traumatic brain injury can benefit from the insights provided by these assays.
What is Bio-Techne’s significance in the life sciences industry?
Bio-Techne is a leading provider of life science tools and reagents, and their innovations drive advancements in both research and clinical diagnostics, ultimately impacting precision medicine.
